{"id":1937,"date":"2016-07-09T04:29:14","date_gmt":"2016-07-09T04:29:14","guid":{"rendered":"http:\/\/zestmag.com\/online\/?p=1937"},"modified":"2016-07-09T04:29:14","modified_gmt":"2016-07-09T04:29:14","slug":"hope-to-alzheimers-sufferers-with-wearable-low-level-light-therapy","status":"publish","type":"post","link":"http:\/\/zestmag.com\/online\/hope-to-alzheimers-sufferers-with-wearable-low-level-light-therapy\/","title":{"rendered":"Hope to Alzheimer&#8217;s sufferers with wearable low-level light therapy"},"content":{"rendered":"<p><strong>Last year, a randomized placebo-controlled pilot study using patented <\/strong><a class=\"linkOnClick\" href=\"https:\/\/vielight.com\/product\/vielight-810\/\" target=\"_blank\" rel=\"nofollow\" data-include=\"300295886\"><strong>Vielight 810 Infrared<\/strong><\/a><strong>\u00a0and patent-pending <\/strong><a class=\"linkOnClick\" href=\"http:\/\/vielight.com\/neuro-transcranial-intranasal-light\/\" target=\"_blank\" rel=\"nofollow\" data-include=\"300295886\"><strong>Vielight Neuro<\/strong><\/a>\u00a0<strong>wearable devices was conducted involving 19 patients affected by Alzheimer&#8217;s disease or dementia. The findings showed surprisingly promising outcomes<\/strong>. <strong>The devices were developed by Vielight Inc. of <span class=\"xn-location\">Toronto, Canada<\/span>.<\/strong><\/p>\n<p><a href=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/07\/Alzheimer.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-1938\" src=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/07\/Alzheimer.jpg\" alt=\"Alzheimer\" width=\"622\" height=\"432\" srcset=\"http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/07\/Alzheimer.jpg 622w, http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/07\/Alzheimer-300x208.jpg 300w, http:\/\/zestmag.com\/online\/wp-content\/uploads\/2016\/07\/Alzheimer-50x35.jpg 50w\" sizes=\"auto, (max-width: 622px) 100vw, 622px\" \/><\/a><\/p>\n<p>This could be the first randomized controlled human study that has presented the arrest or reversal in the decline of Alzheimer&#8217;s Disease. The patients used the &#8220;Neuro&#8221; for 20 minutes once or twice a week and the &#8220;Vielight 810&#8221; every day for 25 minutes. The results of this pilot study are significant and strongly suggest that the treatment for people with moderate-severe cognitive impairment can result in significant clinical improvements. People with this level of cognitive impairment are excluded as candidates for pharmaceutical drugs under development or in clinical trials.<\/p>\n<p id=\"continue-jump\">The details of this study (co-authors include Dr. <span class=\"xn-person\">Margaret Naeser<\/span>, a research professor of neurology at the <span class=\"xn-org\">Boston University School of Medicine<\/span>, Dr. <span class=\"xn-person\">Michael Hamblin<\/span>, an associate professor at <span class=\"xn-org\">Harvard Medical School<\/span>) are now being written into a peer-reviewed paper for publication.<\/p>\n<p>The technology involved the science of low level light therapy (LLLT) or photobiomodulation therapy (PBMT). PBMT is a process in which exposure to low-level light or light emitting diodes stimulate cellular function leading to beneficial clinical effects. Prior to this study, research has already presented its potential with dementia and Alzheimer&#8217;s disease (AD) in its successful effect on animals with AD. Vielight has translated the research into non-invasive wearable devices which were used in this study.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The results of this pilot study are significant and strongly suggest that the treatment for people with moderate-severe cognitive impairment can result in significant clinical improvements. People with this level of cognitive impairment are excluded as candidates for pharmaceutical drugs under development or in clinical trials.<\/p>\n","protected":false},"author":3,"featured_media":1938,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,4,35],"tags":[921,19,1133,20],"class_list":["post-1937","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-wellness-2","category-newsmakers","category-wellness-2","tag-alzheimers-disease","tag-health","tag-vielight-neuro","tag-wellness"],"_links":{"self":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/comments?post=1937"}],"version-history":[{"count":1,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1937\/revisions"}],"predecessor-version":[{"id":1939,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/1937\/revisions\/1939"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media\/1938"}],"wp:attachment":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media?parent=1937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/categories?post=1937"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/tags?post=1937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}